CMP: ₹ 2183

Target: ₹ 2700 (+24%)

Target Period: 12 months

BU

July 25, 2023

Particulars	
Particular	Amount
Market Capitalization	₹ 7599 crore
Total Debt (CY22)	₹ 0 crore
Cash & Inv. (CY22)	₹ 260.2 crore
EV	₹ 7338.8 crore
52 week H/L (₹)	2357 / 1414
Equity capital	₹ 34.8 crore
Face value	₹ 10

Shareholding Pattern							
Jun-22 Sep-22 Dec-22 Mar-23							
Promoter	66.7	66.7	66.7	66.7			
FII	2.9	3.2	3.2	3.5			
DII	10.9	10.8	10.9	10.4			
Others	19.5	19.4	19.2	19.4			

Risks to our call

- Slowdown in domestic and global capex
- Increase in competition in domestic & export markets
- 3) Increase in commodity prices

Price	Pert	ormance		
180				Ym
130		who who	hay work the	
80	~~~			
30 01-Δ	pr-22	06-Sep-22	11-Feb-23	
3170	P	— KSB —	NSE 500	. 5 641 26

Research Analyst

Chirag Shah shah.chirag@icicisecurities.com

Vijay Goel vijay.goel@icicisecurities.com

Riding a strong capex cycle...

About the stock: KSB Ltd (KSB) is a leading international manufacturer of pumps and valves. KSB specializes in centrifugal end suction pumps, high pressure multistage pumps, industrial gate, globe, check valves, submersible motor pumps, monobloc & mini monobloc pumps, hydro pneumatic systems and control valves

- Company has six manufacturing units in India, five in Maharashtra and one in Tamil Nadu. Pumps segment derives ~84% of revenues
- Consolidated revenue grew ~12% CAGR during CY19-22 while EBITDA and PAT have grown by ~18% and ~22% CAGR respectively over the same period. In CY22, revenue and PAT stood at ₹ 1822 crore and ₹ 182.7 crore

Key Investment Thesis:

- Rise in industrial capex provides robust outlook for pumps & valves industry: Increasing capex in infra segments (like housing, irrigation, sanitation, drinking water supply, hospitality, real estate etc) and industrials (like refineries, petrochemicals, pharmaceuticals, chemicals, water treatment, power, steel, cement etc) is set to benefit the Indian pumps & valves industry significantly in the coming period. KSB, one of the leading suppliers in organised pumps and valves market in India, is set to benefit from the robust capex outlook
- Expanding product portfolio with focus on after-market segment: The company, which already caters to different segments like petrochemicals, chemicals, agriculture, solar, nuclear, buildings, waste water management, continues to focus on increasing its market presence in newer segments (like firefighting, railways etc) through expanding product offerings and distribution network. The company has been able to meet the market demand by continuous investments in its plants, products and infrastructure. Moreover, with the technology acquisition of BP & CL, company's emphasis is on increasing its aftermarket business with continued focus on availability of spares and service

Rating and Target Price

- KSB is well positioned to benefit significantly from increasing capex in infra and industrials. With focus on expanding market share with new products and increasing after-market business, we believe KSB's operational and financial performance in the coming period would be considerably better. We estimate revenue and PAT to grow at ~16% and ~21% CAGR over CY22-24E. Balance sheet remains strong with healthy return ratios
- We maintain our **BUY** rating on the stock
- We value KSB at ₹ 2700 per share (based on 35x FY25 EPS)

Key Financial Summary								
(Year-end December)	CY19	CY20	CY21	CY22	3 Year CAGR (CY19-22)	CY23E	CY24E	2 Year CAGR (CY22-CY24E)
Revenue	1,293.9	1,208.1	1,497.3	1,822.0	12.1	2,128.3	2,440.6	15.7
EBITDA	151.7	167.8	209.4	246.7	17.6	304.6	356.2	20.2
EBITDA margin (%)	11.7	13.9	14.0	13.5		14.3	14.6	
Net Profit	100.7	93.8	149.4	182.7	22.0	228.2	268.5	21.2
EPS (₹)	28.9	26.9	42.9	52.5		65.6	77.1	
P/E (x)	75.4	81.0	50.9	41.6		33.3	28.3	
EV/EBITDA (x)	48.6	43.2	34.6	29.7		23.9	20.2	
RoCE (%)	11.9	13.3	16.4	17.6		19.6	20.1	
RoE (%)	12.2	10.5	14.8	16.0		17.5	17.9	

Source: Company, ICICI Direct Research

Conviction Idea

Company Background


KSB Limited (KSB), founded in 1960, is a leading international manufacturer of pumps, valves, systems and control valves. KSB specializes in centrifugal end suction pumps, high pressure multistage pumps, industrial gate, globe, check valves, submersible motor pumps, monobloc & mini monobloc pumps, hydro pneumatic systems and control valves

The Company has six manufacturing units (five in Maharashtra and one in Tamil Nadu) and all facilities are fully equipped designing, testing, fabricating and quality-assure on all aspects of fluid mechanics in India. In Maharashtra, plants are located at Pimpri (Pune), Chinchwad (Pune), Vambori (Ahmednagar), Kesurdi (Satara) and Sinnar (Nashik) while in Tamil Nadu, plant is located at NSN Palayam (Coimbatore).


With these manufacturing locations across India, the company has presence across the country with its own sales & marketing companies and service operations. Company has wide distribution network comprising of 4 zonal offices, 14 branch offices, 800+ authorized dealers, 6 service stations, 200+ authorized service centers and 20 godowns. Company's client portfolio includes BHEL, Indian Oil Corp, Thermax, NTPC, ISGEC, Megha Engineering, Larsen & Toubro, ThyssenKrupp

Pumps segment contributes $\sim\!84\%$ to the revenue ($\sim\!48\%$ from standard pumps, $\sim\!20\%$ from engineered pumps and $\sim\!15\%$ from SupremeServ) while balance $\sim\!16\%$ is from Valves segment. In terms of geographical mix, $\sim\!84\%$ is from domestic markets while $\sim\!16\%$ is from exports

Consolidated revenue of the company has grown by ~12% CAGR in the last 3 years during the period CY19-22 while EBITDA and PAT have grown by ~18% and ~22% CAGR respectively over the same period. During CY22, company reported revenues of ₹ 1822 crore which increased by 21.7% YoY. EBITDA grew by 17.8% YoY to ₹ 246.7 crore while PAT increased by 22.3% YoY to ₹ 182.7 crore in CY22



Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research

Investment Rationale

Robust capex outlook (infra + industrials) to drive demand for pumps & valves

Increase in infrastructure capex (in segments like rural & urban housing, irrigation, sanitation, drinking water supply, hospitality, real estate etc) and increase in industrial capex across industries (like refineries, petrochemicals, pharmaceuticals, chemicals, water treatment, power, steel, cement etc) is set to benefit the Indian pumps & valves industry in the coming period

KSB, a renowned manufacturer and one of the leading suppliers in organised pumps and valves market in India is set to benefit from the increase in domestic capex led by its strong technical expertise and market presence across the country KSB already has approvals for its products from many prestigious companies which gives strong visibility in terms of eligibility of KSB in order inflows from those companies. During CY22, company received customer approvals from Thermax, Siemens, Triveni Turbines, Mitsubishi Japan, NPCIL (Nuclear Power corporation of India), Bechtel (United States) for its products.

Company's order inflow stood at ₹ 2046 crore in CY22 which included orders for standard pumps, engineered pumps, valves and stores & repairs/after-market. In terms of industries mix, the orders were from different segments like petrochemicals, chemicals, agriculture, solar, nuclear, buildings, waste water management etc. The company received the large order of ₹ 501 crore from NPCIL for 8 Reactor Coolant Pumps for Kaiga 5 & 6 reactors for the 700 MW nuclear power plant. Going forward, company expects annual order inflow of ~₹ 2500 crore by CY24, led by further pickup in infra & industrial capex cycle and company's diversification in new growth areas

Expanding product portfolio with focus on after-market

The company continues to focus on increasing its market share and presence in existing and newer segments through expanding product offerings and wide distribution network. The company has launched several new products for segments like firefighting, railways, building, water waste management etc


The company has been able to meet the market demand by continuous investments in its plants, products and infrastructure. For e.g., the company has expanded its Sinnar plant capacity which produces standard pumps. It has also completed the investment in its steel foundry unit to upscale the capacities. Moreover, the company has set up new sales offices at Patna & Guwahati to increase its focus on the eastern/north-eastern parts of India and opened an office at Dhaka to expand its footprints in Bangladesh market. The company has also added mechanical seals (required for the new NPCIL order) manufacturing and testing facility at Shirwal (Satara). Moreover, to support the new business vertical for mechanical seals, the company inaugurated the first mechanical seal repair centre at Chinchwad (Pune)

Company's emphasis on increasing its aftermarket business is continued with focus on availability of spares and service on demand. Company is also continuously evaluating various inorganic growth opportunities in order to further increase its market offerings and reach. As part of this strategy, the company acquired the technology of Bharat Pumps and Compressors (BP & CL), which will enable KSB to serve the industry with spares supplies apart from generating business from selling pumps for various critical applications. Also, capacity of Central Warehouse (Chinchwad) has been expanded to cater the increasing demand for spare parts

Products	Applications
High pressure multistage pumps, Vertical in line pumps, GGC & Ball Valves	For boiler feed applications, condensate extraction, etc.
End suction pumps, process pumps, non clog pumps, high pressure multistage pumps, confirming API 610 latest edition, GGC & Ball Valves	For boiler feed applications, oil & gas, sugar, paper and pulp, handling of Thermic fluids, petrochemicals, etc.
Submersible pumpsets, openwell monobloc pumps, mini-monobloc pumps, dewatering pumps, Solar products, GGC & ball valves,	Irrigation, farm houses, fire fighting, drinking water supply, etc
Submersible Motor non clog pumps, horizontal Non clog end suction pumps, GGC & Ball Valves	Various types of Municipal & Industrial waste water, sewage, effluent transport & treatment storm water drainage & dewatering, etc.
Submersible pumpsets, openwell monobloc pumps, mini-monobloc pumps, dewatering pumps, booster systems, GGC & Ball Valves	Drinking water supply, fire fighting, HVAC, etc
	High pressure multistage pumps, Vertical in line pumps, GGC & Ball Valves End suction pumps, process pumps, non clog pumps, high pressure multistage pumps, confirming API 610 latest edition, GGC & Ball Valves Submersible pumpsets, openwell monobloc pumps, mini-monobloc pumps, dewatering pumps, Solar products, GGC & ball valves, Submersible Motor non clog pumps, horizontal Non clog end suction pumps, GGC & Ball Valves Submersible pumpsets, openwell monobloc pumps, mini-monobloc pumps, dewatering

Revenue growth expected at ~16% CAGR over CY22-24E

KSB's consolidated revenue grew at 12.1% CAGR over the last 3 years (CY19-22). However, over the next two years, revenue growth is expected to be better at 15.7% CAGR over CY22-24E led by better demand scenario of pumps & valves coupled with focus on expanding product portfolio, distribution network and increase in aftersales business





Source: Company, ICICI Direct Research

EBITDA margins expected to improve to ~14.5% in CY23-24E

EBITDA margin improved to 13.5% in CY22 from 11.7% in CY19, which led to EBITDA CAGR at 17.6% during CY19-22 to ₹ 246.7 crore in CY22. Going ahead, we expect EBITDA margin at ~14.5% over CY23-24E, mainly led by positive operating leverage and company's focus on increasing its after-sales business – SupremeServ (from ~15% at present to ~20% in the coming periods).

Thus, on account of increase in revenues and margins, EBITDA is expected to grow at 20.2% CAGR over CY22-24E






Source: Company, ICICI Direct Research

Healthy return ratios

Return ratios have improved gradually in the last 4 years led by prudence in capital allocation and increase in profitability. RoCE (Return on Capital Employed) stood at 17.6% in CY22 as against 10.8% in CY18 while RoE (Return on Equity) improved to 16% in CY22 vs 9.2% in CY18. Going ahead by CY24E, we expect return ratios to improve further with RoCE at $\sim\!20\%$ and RoE at $\sim\!18\%$ in CY24E led by increase in profitability on better sales growth and margins



Key risk and concerns

Slow-down in capex cycle

KSB's revenue and profitability growth is primarily dependent on the demand of pumps and valves in domestic market, which is dependent on public and industrial capex. Any slow-down in the capex cycle in the Industry and infrastructure may hurt the demand for pumps and valves.

Increase in competition in domestic market

KSB derives ~86% of its revenues from domestic markets. Any increase in competition in domestic market from local and MNCs put pressure on sales & pricing of products which may impact sales, margins, profitability and cash flows

Prolonged global slowdown

Company's \sim 14% of revenue comes from exports. Any prolonged slowdown in exports may impact export sales and thus profitability and cash flows

Increase in raw material prices

Steel and copper are the primary raw materials for the company in manufacturing pumps and valves. Any increase in prices of these commodities may impact margins and profitability



Financial summary

Exhibit 8: Profit and loss	₹ crore			
(Year-end Dec)	CY21	CY22	CY23E	CY24E
Total Operating Income	1497.3	1822.0	2128.3	2440.6
Growth (%)	23.9	21.7	16.8	14.7
Raw Material Expenses	792.4	988.0	1,142.9	1,313.0
Employee Expenses	215.4	243.9	275.6	311.4
Other Operating Expense	280.1	343.4	405.2	459.9
Total Operating Expenditure	1,287.9	1,575.3	1,823.7	2,084.4
EBITDA	209.4	246.7	304.6	356.2
Growth (%)	24.8	17.8	23.5	16.9
Depreciation	43.5	45.3	49.0	55.0
Interest	5.0	6.1	6.0	6.0
Other Income	33.7	42.2	50.0	60.0
PBT	194.6	237.5	299.6	355.2
Exceptional Item	0.0	0.0	0.0	0.0
Total Tax	51.6	62.6	79.4	94.7
PAT	143.0	174.9	220.2	260.5
Profit from Associates	6.4	7.8	8.0	8.0
Reported Net Profit	149.4	182.7	228.2	268.5
Growth (%)	61.6	22.3	25.9	18.3
EPS (₹)	42.9	52.5	65.6	77.1

Source: Company, ICICI Direct Research

Exhibit 9: Cash flow state	ment			₹ crore
(Year-end Dec)	CY21	CY22	CY23E	CY24E
Profit after Tax	149.4	182.7	228.2	268.5
Add: Depreciation	43.5	45.3	49.0	55.0
(Inc)/dec in Current Assets	-77.8	-247.1	-203.1	-151.7
Inc/(dec) in CL and Provisions	9.0	82.4	127.7	92.9
Others	5.0	6.1	6.0	6.0
CF from Operations	129.1	69.4	207.8	270.7
(Inc)/dec in Investments	-3.5	-4.5	0.0	0.0
(Inc)/dec in Fixed Assets	-49.8	-70.7	-85.0	-85.0
Others	-30.4	-32.0	-50.0	-90.0
CF from Investing	-83.7	-107.2	-135.0	-175.0
Issue/(Buy back) of Equity	0.0	0.0	0.0	0.0
Inc/(dec) in loan funds	-60.0	0.0	0.0	0.0
Dividend paid & dividend tax	-29.6	-52.2	-62.7	-74.8
Inc/(dec) in Share Cap	0.0	0.0	0.0	0.0
Others	-4.6	-4.3	-7.8	-6.0
CF from Financing	-94.2	-56.5	-70.5	-80.8
Net Cash flow	-48.8	-94.3	2.4	14.9
Opening Cash	403.4	354.5	260.2	262.6
Closing Cash	354.5	260.2	262.6	277.5

Source: Company, ICICI Direct Research

Exhibit 10: Balance sh	eet			₹ crore
(Year-end Dec)	CY21	CY22	CY23E	CY24E
Liabilities				
Equity Capital	34.8	34.8	34.8	34.8
Reserve and Surplus	976.0	1,108.3	1,272.0	1,465.
Total Shareholders funds	1,010.8	1,143.1	1,306.9	1,500.
Total Debt	0.0	0.0	0.0	0.0
Total Liabilities	1,010.8	1,143.1	1,306.9	1,500.5
Assets				
Gross Block	728.6	813.4	898.5	983.
Less: Acc Depreciation	418.0	463.3	512.3	567.3
Net Block	310.6	350.1	386.2	416.3
Capital WIP	39.2	25.1	25.0	25.0
Total Fixed Assets	349.8	375.2	411.2	441.2
Liquid Investments	0.0	0.0	50.0	140.0
Other Investments	69.7	74.2	74.2	74.:
Inventory	423.1	561.1	653.1	735.
Debtors	278.0	403.7	478.1	534.
Loans and Advances	12.8	12.9	18.2	20.9
Other Current Assets	51.8	35.1	66.5	76.2
Cash	354.5	260.2	262.6	277.
Total Current Assets	1,120.2	1,273.0	1,478.5	1,645.0
Creditors	279.2	314.3	379.0	434.0
Provisions	105.7	93.6	131.0	148.
Other Current Liabilities	213.6	273.0	298.6	318.
Total Current Liabilities	598.5	680.9	808.6	901.
Net Current Assets	521.7	592.1	669.9	743.
Others Assets	69.6	101.6	101.6	101.
Application of Funds	1010.8	1143.1	1306.9	1500.

CY21 CY22 CY23E CY24E Per share data (₹) 8 8 52.5 65.6 77.1 Cash EPS 55.4 65.5 79.6 92.9 BV 290.4 328.4 375.4 431.1 DPS 8.5 15.0 18.0 21.5 Cash Per Share (Incl Invst) 101.9 74.8 89.8 119.9 Operating Ratios (%) 8 15.0 18.0 21.5 Cash Per Share (Incl Invst) 101.9 74.8 89.8 119.9 Operating Ratios (%) 8 13.0 14.1 14.6 PBT / Total Op. income 13.0 13.0 14.1 14.6 PBT / Total Op. income 13.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) 8 16.0 17.5 <th>Exhibit 11: Key ratios</th> <th></th> <th></th> <th></th> <th></th>	Exhibit 11: Key ratios				
EPS 42.9 52.5 65.6 77.1 Cash EPS 55.4 65.5 79.6 92.9 BV 290.4 328.4 375.4 431.1 DPS 8.5 15.0 18.0 21.5 Cash Per Share (Incl Invst) 101.9 74.8 89.8 119.9 Operating Ratios (%) EBITDA Margin 14.0 13.5 14.3 14.6 PBT / Total Op. income 13.0 13.0 14.1 14.6 PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) 8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoCE 16.4 17.6 19.6 20.1 RolC 26.2 24.3 27.2<	(Year-end Dec)	CY21	CY22	CY23E	CY24E
Cash EPS 55.4 65.5 79.6 92.9 BV 290.4 328.4 375.4 431.1 DPS 8.5 15.0 18.0 21.5 Cash Per Share (Incl Invst) 101.9 74.8 89.8 119.9 Operating Ratios (%) EBITDA Margin 14.0 13.5 14.3 14.6 PBT / Total Op. income 13.0 13.0 14.1 14.6 PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) 7 23.9 20.2 EV / Net Sales	Per share data (₹)				
BV 290.4 328.4 375.4 431.1 DPS 8.5 15.0 18.0 21.5 Cash Per Share (Incl Invst) 101.9 74.8 89.8 119.9 Operating Ratios (%) EBITDA Margin 14.0 13.5 14.3 14.6 PBT / Total Op. income 13.0 13.0 14.1 14.6 PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) Ye 50.9 41.6 33.3 28.3 EV / Net Sales 4.8 4.0 3.4 2.9 <td>EPS</td> <td>42.9</td> <td>52.5</td> <td>65.6</td> <td>77.1</td>	EPS	42.9	52.5	65.6	77.1
DPS 8.5 15.0 18.0 21.5 Cash Per Share (Incl Invst) 101.9 74.8 89.8 119.9 Operating Ratios (%) EBITDA Margin 14.0 13.5 14.3 14.6 PBT / Total Op. income 13.0 13.0 14.1 14.6 PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) 68 63 65 65 Return Ratios (%) 7.5 16.4 17.6 19.6 20.1 RoCE 16.4 17.6 19.6 20.1 RolC 26.2 24.3 27.2 29.2 Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / Net Sales 4.8 4.0 3.4 2.9	Cash EPS	55.4	65.5	79.6	92.9
Cash Per Share (Incl Invst) 101.9 74.8 89.8 119.9 Operating Ratios (%) EBITDA Margin 14.0 13.5 14.3 14.6 PBT / Total Op. income 13.0 13.0 14.1 14.6 PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) 8 63 65 65 Return Ratios (%) 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RolC 26.2 24.3 27.2 29.2 Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1	BV	290.4	328.4	375.4	431.1
Departing Ratios (%) EBITDA Margin	DPS	8.5	15.0	18.0	21.5
EBITDA Margin 14.0 13.5 14.3 14.6 PBT / Total Op. income 13.0 13.0 14.1 14.6 PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) Y/E 50.9 41.6 33.3 28.3 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Cash Per Share (Incl Invst)	101.9	74.8	89.8	119.9
PBT / Total Op. income 13.0 13.0 14.1 14.6 PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RolC 26.2 24.3 27.2 29.2 Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7	Operating Ratios (%)				
PAT Margin 10.0 10.0 10.7 11.0 Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) Y/E 50.9 41.6 33.3 28.3 EV / Rebitida 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios 5.1 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	EBITDA Margin	14.0	13.5	14.3	14.6
Inventory days 103 112 112 110 Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) RoE	PBT / Total Op. income	13.0	13.0	14.1	14.6
Debtor days 68 81 82 80 Creditor days 68 63 65 65 Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / Rebitida 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	PAT Margin	10.0	10.0	10.7	11.0
Creditor days 68 63 65 65 Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / RebITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Inventory days	103	112	112	110
Return Ratios (%) RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / RebITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Debtor days	68	81	82	80
RoE 14.8 16.0 17.5 17.9 RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / EBITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Creditor days	68	63	65	65
RoCE 16.4 17.6 19.6 20.1 RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / BITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios 5.1 0.0 0.0 0.0 0.0 Debt/EBITDA 0.0 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Return Ratios (%)				
RoIC 26.2 24.3 27.2 29.2 Valuation Ratios (x) Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / EBITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	RoE	14.8	16.0	17.5	17.9
Valuation Ratios (x) P/E 50.9 41.6 33.3 28.3 EV / EBITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	RoCE	16.4	17.6	19.6	20.1
P/E 50.9 41.6 33.3 28.3 EV / EBITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	RoIC	26.2	24.3	27.2	29.2
EV / EBITDA 34.6 29.7 23.9 20.2 EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Valuation Ratios (x)				
EV / Net Sales 4.8 4.0 3.4 2.9 Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	P/E	50.9	41.6	33.3	28.3
Market Cap / Sales 5.1 4.2 3.6 3.1 Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	EV / EBITDA	34.6	29.7	23.9	20.2
Price to Book Value 7.5 6.6 5.8 5.1 Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	EV / Net Sales	4.8	4.0	3.4	2.9
Solvency Ratios Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Market Cap / Sales	5.1	4.2	3.6	3.1
Debt/EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Price to Book Value	7.5	6.6	5.8	5.1
Debt / Equity 0.0 0.0 0.0 0.0 Current Ratio 1.5 1.7 1.7 1.7	Solvency Ratios				
Current Ratio 1.5 1.7 1.7 1.7	Debt/EBITDA	0.0	0.0	0.0	0.0
	Debt / Equity	0.0	0.0	0.0	0.0
Quick Ratio 0.7 0.7 0.8 0.8	Current Ratio	1.5	1.7	1.7	1.7
	Quick Ratio	0.7	0.7	0.8	0.8

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%; Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
Third Floor, Brillanto House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com



ANALYST CERTIFICATION

I/We, Chirag Shah, PGDBM, Vijay Goel, PGDBM Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Prabodh Avadhoot Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.